260 related articles for article (PubMed ID: 33353838)
21. SUMOylation Modulates CFTR Biogenesis: Is the Pathway Druggable?
Ahner A; Frizzell RA
Curr Drug Targets; 2015; 16(9):965-75. PubMed ID: 26028049
[TBL] [Abstract][Full Text] [Related]
22. Identification of a new small ubiquitin-like modifier (SUMO)-interacting motif in the E3 ligase PIASy.
Kaur K; Park H; Pandey N; Azuma Y; De Guzman RN
J Biol Chem; 2017 Jun; 292(24):10230-10238. PubMed ID: 28455449
[TBL] [Abstract][Full Text] [Related]
23. Sumoylation and Its Contribution to Cancer.
Lee JS; Choi HJ; Baek SH
Adv Exp Med Biol; 2017; 963():283-298. PubMed ID: 28197919
[TBL] [Abstract][Full Text] [Related]
24. Neddylation: a novel modulator of the tumor microenvironment.
Zhou L; Jiang Y; Luo Q; Li L; Jia L
Mol Cancer; 2019 Apr; 18(1):77. PubMed ID: 30943988
[TBL] [Abstract][Full Text] [Related]
25. SUMO-mimicking peptides inhibiting protein SUMOylation.
Zhao B; Villhauer EB; Bhuripanyo K; Kiyokawa H; Schindelin H; Yin J
Chembiochem; 2014 Dec; 15(18):2662-6. PubMed ID: 25412743
[TBL] [Abstract][Full Text] [Related]
26. The SUMO Pathway in Mitosis.
Mukhopadhyay D; Dasso M
Adv Exp Med Biol; 2017; 963():171-184. PubMed ID: 28197912
[TBL] [Abstract][Full Text] [Related]
27. SUMOylation in carcinogenesis.
Bettermann K; Benesch M; Weis S; Haybaeck J
Cancer Lett; 2012 Mar; 316(2):113-25. PubMed ID: 22138131
[TBL] [Abstract][Full Text] [Related]
28. The Effect of Neddylation Inhibition on Inflammation-Induced MMP9 Gene Expression in Esophageal Squamous Cell Carcinoma.
Hryniewicz-Jankowska A; Wierzbicki J; Tabola R; Stach K; Sossey-Alaoui K; Augoff K
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572115
[TBL] [Abstract][Full Text] [Related]
29. Molecular mechanisms in SUMO conjugation.
Varejão N; Lascorz J; Li Y; Reverter D
Biochem Soc Trans; 2020 Feb; 48(1):123-135. PubMed ID: 31872228
[TBL] [Abstract][Full Text] [Related]
30. Cell cycle-dependent conjugation of endogenous BRCA1 protein with SUMO-2/3.
Vialter A; Vincent A; Demidem A; Morvan D; Stepien G; Venezia ND; Rio PG
Biochim Biophys Acta; 2011 Apr; 1810(4):432-8. PubMed ID: 21147198
[TBL] [Abstract][Full Text] [Related]
31. E2-mediated small ubiquitin-like modifier (SUMO) modification of thymine DNA glycosylase is efficient but not selective for the enzyme-product complex.
Coey CT; Fitzgerald ME; Maiti A; Reiter KH; Guzzo CM; Matunis MJ; Drohat AC
J Biol Chem; 2014 May; 289(22):15810-9. PubMed ID: 24753249
[TBL] [Abstract][Full Text] [Related]
32. Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells.
Best S; Lam V; Liu T; Bruss N; Kittai A; Danilova OV; Murray S; Berger A; Pennock ND; Lind EF; Danilov AV
Leukemia; 2021 Jan; 35(1):156-168. PubMed ID: 32203139
[TBL] [Abstract][Full Text] [Related]
33. SUMO and Cytoplasmic RNA Viruses: From Enemies to Best Friends.
El Motiam A; Vidal S; Seoane R; Bouzaher YH; González-Santamaría J; Rivas C
Adv Exp Med Biol; 2020; 1233():263-277. PubMed ID: 32274761
[TBL] [Abstract][Full Text] [Related]
34. Small-molecule inhibitors targeting small ubiquitin-like modifier pathway for the treatment of cancers and other diseases.
Hua D; Wu X
Eur J Med Chem; 2022 Apr; 233():114227. PubMed ID: 35247754
[TBL] [Abstract][Full Text] [Related]
35. Small ubiquitin-like modifier 1-3 conjugation [corrected] is activated in human astrocytic brain tumors and is required for glioblastoma cell survival.
Yang W; Wang L; Roehn G; Pearlstein RD; Ali-Osman F; Pan H; Goldbrunner R; Krantz M; Harms C; Paschen W
Cancer Sci; 2013 Jan; 104(1):70-7. PubMed ID: 23078246
[TBL] [Abstract][Full Text] [Related]
36. Conjugation of human topoisomerase 2 alpha with small ubiquitin-like modifiers 2/3 in response to topoisomerase inhibitors: cell cycle stage and chromosome domain specificity.
Agostinho M; Santos V; Ferreira F; Costa R; Cardoso J; Pinheiro I; Rino J; Jaffray E; Hay RT; Ferreira J
Cancer Res; 2008 Apr; 68(7):2409-18. PubMed ID: 18381449
[TBL] [Abstract][Full Text] [Related]
37. Allosteric Inhibition of Ubiquitin-like Modifications by a Class of Inhibitor of SUMO-Activating Enzyme.
Li YJ; Du L; Wang J; Vega R; Lee TD; Miao Y; Aldana-Masangkay G; Samuels ER; Li B; Ouyang SX; Colayco SA; Bobkova EV; Divlianska DB; Sergienko E; Chung TDY; Fakih M; Chen Y
Cell Chem Biol; 2019 Feb; 26(2):278-288.e6. PubMed ID: 30581133
[TBL] [Abstract][Full Text] [Related]
38. Inhibitors targeting the SUMOylation pathway: A patent review 2012‑2015 (Review).
Zhou Y; Ji C; Cao M; Guo M; Huang W; Ni W; Meng L; Yang H; Wei JF
Int J Mol Med; 2018 Jan; 41(1):3-12. PubMed ID: 29115401
[TBL] [Abstract][Full Text] [Related]
39. Ubiquitin, SUMO, and Nedd8 as Therapeutic Targets in Cancer.
Gâtel P; Piechaczyk M; Bossis G
Adv Exp Med Biol; 2020; 1233():29-54. PubMed ID: 32274752
[TBL] [Abstract][Full Text] [Related]
40. SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243.
Murai Y; Jo U; Murai J; Jenkins LM; Huang SN; Chakka S; Chen L; Cheng K; Fukuda S; Takebe N; Pommier Y
Cancer Res; 2021 Jun; 81(11):3067-3078. PubMed ID: 33863777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
